9MAO image
Deposition Date 2025-03-14
Release Date 2026-08-12
Last Version Date 2026-10-21
Entry Detail
PDB ID:
9MAO
Keywords:
Title:
SARS-CoV-2 spike-Crp5
Biological Source:
Expression System(s):
Method Details:
Experimental Method:
Resolution:
3.09 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Spike glycoprotein
Gene (Uniprot):S
Mutagens:F817P/A892P/A899P/A942P/K986P/V987P
Chain IDs:A (auth: C), B, C (auth: A)
Chain Length:1273
Number of Molecules:3
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Molecule:Alpha-defensin 5
Gene (Uniprot):Defa5
Chain IDs:D
Chain Length:36
Number of Molecules:1
Biological Source:Mus musculus
Ligand Molecules
Primary Citation
Enteric alpha-defensins contribute to intestinal mucosal immunity against SARS-CoV-2 infection.
Mucosal Immunol 19 100392 100392 (2026)
PMID: 42542248 DOI: 10.1016/j.mucimm.2026.100392

Abstact

SARS-CoV-2 primarily targets epithelial cells in the respiratory and intestinal tracts where its cognate receptor ACE2 and obligate processing enzymes furin and TMPRSS2 are richly expressed. However, compared with severe inflammation and tissue damage in the lungs of a COVID-19 patient, clinical lesions in the intestine are rare, suggesting an effective intestinal mucosal immunity against SARS-CoV-2 infection. Here, we report that MMP7(-/-)/hACE2 hybrid mice lacking mature enteric alpha-defensins or cryptdins were more susceptible to SARS-CoV-2 infection in the intestine than K18-hACE2 transgenic mice. The mouse alpha-defensin cryptdin-5 (Crp5) displayed potent and broad antiviral activity in vitro and in vivo by two distinct mechanisms, (1) directly targeting the RBD of the spike (S) protein to antagonize its interactions with ACE2, thus blocking viral attachment, membrane fusion and cell-to-cell transmission, and (2) binding to the 630 loop of the S protein to induce its multimerization, thereby impairing proteolytic processing, membrane fusion and, ultimately, viral infectivity. Our findings imply that enteric alpha-defensins help alleviate, as host protective factors, Covid-19 symptoms in the intestine despite higher ACE2 expression in the gut than in the lungs, and that Crp5 may be developed as a broad-spectrum antiviral for the treatment of coronavirus infection irrespective of virus type and variant.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback